PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23181121-7	2012	Although the IPI remained predictive for the CHOP-like group, it failed to distinguish between the various prognostic categories in the R-CHOP-like group.	diprotin A	13-16	DNA damage inducible transcript 3	Homo sapiens	45-49	
23181121-8	2012	Notably, redistribution of the IPI factors into R-IPI factors identified three discrete prognostic groups with significantly different outcomes in both the CHOP-like and R-CHOP-like groups.	diprotin A	31-34	DNA damage inducible transcript 3	Homo sapiens	156-160	
23181121-8	2012	Notably, redistribution of the IPI factors into R-IPI factors identified three discrete prognostic groups with significantly different outcomes in both the CHOP-like and R-CHOP-like groups.	diprotin A	31-34	DNA damage inducible transcript 3	Homo sapiens	172-176	
22160255-6	2012	But in the CHOP group, IPI still distinguished four risk groups.	diprotin A	23-26	DNA damage inducible transcript 3	Homo sapiens	11-15	
31222719-13	2019	CNS-IPI is valid in elderly R-CHOP-treated DLBCL patients, with the highest risk in those with CNS-IPI 6 and R/A involvement.	diprotin A	4-7	DNA damage inducible transcript 3	Homo sapiens	30-34	
19205655-8	2009	IPI is still important in predicting the prognosis in the R-CHOP era in DLBCL; however, obtaining CR after four cycles of R-CHOP and presence of bulky disease should be considered together.	diprotin A	0-3	DNA damage inducible transcript 3	Homo sapiens	60-64	
21718130-6	2011	The revised IPI better predicted survival than did the standard IPI in patients with DLBCL treated with R-CHOP.	diprotin A	12-15	DNA damage inducible transcript 3	Homo sapiens	106-110	
20385988-11	2010	These results demonstrate that the IPI is still valid in the R-CHOP era.	diprotin A	35-38	DNA damage inducible transcript 3	Homo sapiens	63-67	
19757311-4	2009	PKC-beta II expression correlated with inferior overall survival (OS) and progression-free survival (PFS) in CHOP-treated patients with low-risk International Prognostic Index (IPI) disease (0-2 adverse factors), but not in the overall patient group unstratified by IPI.	diprotin A	177-180	DNA damage inducible transcript 3	Homo sapiens	109-113	
26424560-0	2016	MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.	diprotin A	57-60	DNA damage inducible transcript 3	Homo sapiens	180-184	
29081194-7	2017	NCCN-IPI was outstanding to identify the subgroup of low risk patients with PTCL, who may benefit from conventional chemotherapy such as CHOP or CHOP-like regimen.	diprotin A	5-8	DNA damage inducible transcript 3	Homo sapiens	137-141	
29081194-7	2017	NCCN-IPI was outstanding to identify the subgroup of low risk patients with PTCL, who may benefit from conventional chemotherapy such as CHOP or CHOP-like regimen.	diprotin A	5-8	DNA damage inducible transcript 3	Homo sapiens	145-149	
27760757-9	2016	The combined molecular and clinical prognostic indices, M-IPI-R and IPI+IHC, have remarkable predictive values in R-CHOP-treated DLBCL.	diprotin A	58-61	DNA damage inducible transcript 3	Homo sapiens	116-120	
26424560-8	2016	In the era of R-CHOP treatment, MYC and BCL-2 adjusted-IPI is more powerful than the IPI for helping guide treatment planning and interpretation of clinical trials.	diprotin A	55-58	DNA damage inducible transcript 3	Homo sapiens	16-20	
26035406-7	2015	CONCLUSIONS: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with F-fluoro-2-deoxy-d-glucose positron emission tomography-based complete response after first-line R-CHOP therapy.	diprotin A	22-25	DNA damage inducible transcript 3	Homo sapiens	201-205	
23775435-7	2013	We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012).	diprotin A	45-48	DNA damage inducible transcript 3	Homo sapiens	125-129	
23984080-8	2013	To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort.	diprotin A	120-123	DNA damage inducible transcript 3	Homo sapiens	89-93	
23335369-8	2013	A combined immunohistochemical or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP.	diprotin A	205-208	DNA damage inducible transcript 3	Homo sapiens	242-246